No evidence of neurotoxicity exists
- 17 August 1996
- Vol. 313 (7054) , 423
- https://doi.org/10.1136/bmj.313.7054.423a
Abstract
Reference 1.↵ Green AR, Goodwin GM .Ecstasy and neurodegeneration.BMJ 1996;312: 1493–4. (15 June.) 2.↵ Colado MI, Murray TK, Green AR .5-HT loss in rat brain following 3, 4-methylenedioxymethamphetamine (MDMA), p-choroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.Br J Pharmacol 1993;108: 583–9. 3.↵ Wilson JM, Kalasinsky KS, Levery AI, Bergeron C, Reibel G, Anthony RM et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.Nature Medicine 1996;2: 699–703. 4.↵ Beck J, Morgan P .Designer drug confusion: a focus on MDMA.J Drug Educ 1986;16: 267–82. 5.↵ McGuire PK, Cope H, Fahy TA .Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (“Ecstasy”).Br J Psychiatry 1994;165: 391–5.Keywords
This publication has 4 references indexed in Scilit:
- Ecstasy and neurodegenerationBMJ, 1996
- Striatal dopamine nerve terminal markers in human, chronic methamphetamine usersNature Medicine, 1996
- Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’)The British Journal of Psychiatry, 1994
- 5‐HT loss in rat brain following 3, 4‐methylenedioxymethamphetamine (MDMA), p‐chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpineBritish Journal of Pharmacology, 1993